Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

184 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn's disease in children: REACH open-label extension.
Hyams J, Walters TD, Crandall W, Kugathasan S, Griffiths A, Blank M, Johanns J, Lang Y, Markowitz J, Cohen S, Winter HS, Veereman-Wauters G, Ferry G, Baldassano R. Hyams J, et al. Among authors: winter hs. Curr Med Res Opin. 2011 Mar;27(3):651-62. doi: 10.1185/03007995.2010.547575. Epub 2011 Jan 18. Curr Med Res Opin. 2011. PMID: 21241207 Clinical Trial.
Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis.
Hyams J, Damaraju L, Blank M, Johanns J, Guzzo C, Winter HS, Kugathasan S, Cohen S, Markowitz J, Escher JC, Veereman-Wauters G, Crandall W, Baldassano R, Griffiths A; T72 Study Group. Hyams J, et al. Among authors: winter hs. Clin Gastroenterol Hepatol. 2012 Apr;10(4):391-9.e1. doi: 10.1016/j.cgh.2011.11.026. Epub 2011 Dec 8. Clin Gastroenterol Hepatol. 2012. PMID: 22155755 Clinical Trial.
Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.
Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, Liu G, Travers S, Heuschkel R, Markowitz J, Cohen S, Winter H, Veereman-Wauters G, Ferry G, Baldassano R; REACH Study Group. Hyams J, et al. Gastroenterology. 2007 Mar;132(3):863-73; quiz 1165-6. doi: 10.1053/j.gastro.2006.12.003. Epub 2006 Dec 3. Gastroenterology. 2007. PMID: 17324398 Clinical Trial.
Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease.
Baldassano R, Braegger CP, Escher JC, DeWoody K, Hendricks DF, Keenan GF, Winter HS. Baldassano R, et al. Among authors: winter hs. Am J Gastroenterol. 2003 Apr;98(4):833-8. doi: 10.1111/j.1572-0241.2003.07343.x. Am J Gastroenterol. 2003. PMID: 12738464 Clinical Trial.
Phase I trial of sargramostim in pediatric Crohn's disease.
Kelsen JR, Rosh J, Heyman M, Winter HS, Ferry G, Cohen S, Mamula P, Baldassano RN. Kelsen JR, et al. Among authors: winter hs. Inflamm Bowel Dis. 2010 Jul;16(7):1203-8. doi: 10.1002/ibd.21204. Inflamm Bowel Dis. 2010. PMID: 20052780 Clinical Trial.
Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease.
Hyams JS, Dubinsky MC, Baldassano RN, Colletti RB, Cucchiara S, Escher J, Faubion W, Fell J, Gold BD, Griffiths A, Koletzko S, Kugathasan S, Markowitz J, Ruemmele FM, Veereman G, Winter H, Masel N, Shin CR, Tang KL, Thayu M. Hyams JS, et al. Gastroenterology. 2017 Jun;152(8):1901-1914.e3. doi: 10.1053/j.gastro.2017.02.004. Epub 2017 Feb 11. Gastroenterology. 2017. PMID: 28193515
184 results